GLP-1 Over 65: What the Labels, Trials and Medicare Rules Show

None of the four US labels for Wegovy, Ozempic, Zepbound or Mounjaro sets an upper age limit, and the dosing sections of these labels list no dose based on age. Each label carries a Geriatric Use section (8.5) that reports no overall differences in safety or effectiveness between patients 65 and older and younger adults, based on the trials submitted for approval ^[1][2][3][4]. Semaglutide is approved for type 2 diabetes and obesity with no upper age limit ^[6].

The fuller picture from pooled analyses is mostly reassuring but has real caveats. Weight loss, heart and metabolic benefits appear broadly comparable in adults 65 and older versus younger adults for both semaglutide and tirzepatide ^[5][6]. The main differences are tolerability: side effects force older adults to stop these drugs more often than younger adults, and the Wegovy label reports an imbalance in hip and pelvis fractures among trial patients 75 and older ^[1][5][6]. On the payment side, Medicare’s GLP-1 Bridge demonstration covers certain drugs for a flat $50 per one-month supply from July 1, 2026 through December 31, 2027 ^[13][14].

Is there a maximum age for Ozempic, Wegovy, Zepbound or Mounjaro?

No. Each of the four labels includes a Geriatric Use section 8.5, and none sets an age cutoff. The dosing sections of these labels list no dose based on age ^[1][2][3][4]. Semaglutide is approved for type 2 diabetes and for obesity with no upper age limit ^[6].

The labels differ in how many older adults were in the underlying trials. The Mounjaro label states that across a pool of seven trials, 1,539 (30.1%) of tirzepatide-treated patients were 65 or older and 212 (4.1%) were 75 or older, and that in the cardiovascular outcomes trial the shares were 3,327 (50%) and 705 (11%). The label states no overall differences in safety or effectiveness were observed between patients 65 and older and younger patients ^[4]. The Zepbound label states that in a pool of two fixed-dose weight-reduction studies, 226 (9%) of tirzepatide-treated patients were 65 or older and 13 (0.5%) were 75 or older, with no overall differences in safety or effectiveness by age. The label also states that the Zepbound obstructive sleep apnea studies did not include enough patients 65 or older to determine whether they respond differently from younger patients ^[3].

The label revision dates printed in the sources are: Wegovy 06/2026, Ozempic 05/2026, Zepbound 8/2026 and Mounjaro 8/2026 ^[1][2][3][4].

What does the Ozempic label say about patients 65 and older?

The Ozempic label reports that in the pool of placebo- and active-controlled glycemic control trials, 744 (23.6%) of Ozempic-treated patients were 65 or older and 102 (3.2%) were 75 or older. In SUSTAIN 6, the cardiovascular outcomes trial, 788 (48%) were 65 or older and 157 (9.6%) were 75 or older ^[2].

The label states that no overall differences in safety or efficacy were detected between these patients and younger patients, but that greater sensitivity of some older individuals cannot be ruled out ^[2].

What is the hip and pelvis fracture note in the Wegovy label?

The Wegovy label reports a fracture imbalance in one trial subgroup. In the cardiovascular outcomes trial, patients 75 and older reported more hip and pelvis fractures in the Wegovy injection arm than in the placebo arm: 2.4% (17 of 703) on Wegovy versus 0.6% (4 of 663) on placebo. Among females in that trial, the rates were 1% (24 of 2,448) on Wegovy versus 0.2% (5 of 2,424) on placebo ^[1].

This is a subgroup imbalance reported in the label’s Geriatric Use and Adverse Reactions sections, not a boxed warning, a contraindication or an established causal effect. The same label passage states that patients 75 and older in both treatment arms reported more serious adverse reactions overall than younger adults, and that no overall difference in effectiveness was observed between patients 65 and older and younger patients ^[1].

For context on trial composition, the label states that in the Wegovy injection weight trials, 233 (9%) of treated patients were 65 to under 75 and 23 (1%) were 75 or older; in the tablet trial, 16 (8%) and 5 (2%). In the cardiovascular outcomes trial, 2,656 (30%) were 65 to 75 and 703 (8%) were 75 or older ^[1]. In the MASH trial, 138 of 534 (26%) randomized patients were 65 or older and 13 (2%) were 75 or older; fractures occurred in 4.4% of Wegovy-treated patients (2.6 cases per 100 patient-years) versus 3.3% of placebo-treated patients (2 cases per 100 patient-years), with no overall age differences in safety or effectiveness ^[1].

How well does tirzepatide work in adults 65 and older?

A post hoc analysis published on 16 June 2026 in Diabetes, Obesity and Metabolism pooled SURMOUNT-1 through -5 (including the SURMOUNT-1 three-year study), SURMOUNT-OSA and SUMMIT, comparing participants 65 and older with those under 65 across tirzepatide doses up to 15 mg ^[5].

The analysis found that tirzepatide was associated with clinically meaningful weight reduction and favorable treatment differences in cardiometabolic risk factors and quality-of-life measures in adults 65 and older, with results broadly comparable to adults under 65 ^[5]. In SURMOUNT-1, DXA scans at week 72 showed greater reductions with tirzepatide than placebo in fat mass, lean mass, visceral fat and the fat-to-lean ratio, with comparable results in both age groups ^[5].

One outcome split by age: in SURMOUNT-OSA, treatment differences in the apnea-hypopnea index favored tirzepatide in participants under 65, while in those 65 and older the confidence intervals were wide and included zero ^[5]. Several authors of the analysis are Eli Lilly employees, and the authors conclude that the analysis supports tirzepatide’s use in older adults when weighing risks and benefits ^[5].

Are side effects worse, or more likely to force stopping, after 65?

Side effect rates are similar, but older adults stop the drugs more often. In the pooled tirzepatide safety set (586 patients 65 and older on tirzepatide, 340 on placebo), discontinuation due to adverse events occurred in 13.0% of tirzepatide patients 65 and older versus 6.8% on placebo; under 65, the rates were 6.6% versus 3.0% ^[5].

Outcome, adults 65 and older	Tirzepatide	Placebo
Discontinuation due to adverse event	13.0%	6.8%
Serious adverse events	19.5%	25.3%
GI adverse events as reason for stopping	7.0%	0
Falls	3.6%	3.5%
Limb fractures	1.5%	3.2%
Heart failure hospitalization	1.2%	5.9%
Acute kidney injury	2.1%	2.4%
Pancreatitis	0.7%	0%

All figures are from the pooled tirzepatide analysis ^[5]. Gastrointestinal events were the leading reason older adults stopped tirzepatide, with nausea the most common cause ^[5].

The semaglutide picture is similar. A pooled analysis of 22 trials from the PIONEER, SUSTAIN and STEP programs, published on 6 May 2025, included 3,529 participants 65 or older and was done in part to inform the design of the evoke and evoke+ Alzheimer’s trials; several authors are Novo Nordisk employees ^[6]. Any adverse event on semaglutide occurred in 73.6% to 92.4% of participants 65 or older versus 73.2% to 90.8% of the overall population. Events leading to permanent discontinuation were more frequent in the older group: 9.3% to 12.4% versus 5.7% to 8.7% overall. Gastrointestinal disorders were the most frequent events in both groups, 44.6% to 73.8% in those 65 and older versus 39.1% to 73.4% overall ^[6].

How much weight do older adults lose on these drugs?

In a smaller subset of participants 65 and older in the pooled semaglutide analysis, estimated weight loss was 3.8% at week 52 versus 0.1% with placebo. Baseline BMI in the 65-and-older groups ranged from 29.7 to 35.4, and the subset included participants with type 2 diabetes ^[6].

For tirzepatide, the post hoc analysis reported clinically meaningful weight reduction in adults 65 and older that was broadly comparable to adults under 65, along with comparable improvements in cardiometabolic risk factors and quality-of-life measures ^[5].

Do GLP-1s cause muscle loss or sarcopenia in older adults?

They reduce lean mass, and the size of that effect is now quantified. A systematic review and meta-analysis published on 12 September 2026 in Drugs, conducted by the WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Aging in Liège at the World Health Organization’s request, analyzed 60 articles (46 randomized trials, 13 real-world evidence studies and one pharmacovigilance study) covering 1,250,717 individuals, with searches through March 2025 ^[7].

In the pooled model across 28 comparisons, GLP-1 receptor agonists reduced lean body mass or fat-free mass versus comparators with a standardized mean difference of -0.52 (95% CI -0.8 to -0.23), with high heterogeneity (I2 88%). The finding was robust in all sensitivity analyses and was driven mainly by liraglutide and semaglutide compared with placebo ^[7].

The certainty of evidence was rated low, and the changes appeared largely related to weight loss overall. Whether these changes translate into clinically meaningful impairments in muscle function or physical performance remains uncertain, and the review’s authors state that studies of strength and performance are needed ^[7]. The same meta-analysis found no effect on bone mineral density or fractures in the most adjusted models, and no significant change in WOMAC pain, function or stiffness scores ^[7].

The concern for older adults specifically is spelled out in the tirzepatide post hoc analysis: older adults often have diminished muscle mass and anabolic resistance, predisposing them to sarcopenia, and even modest muscle loss can impair physical function and worsen frailty ^[5].

Do GLP-1s raise or lower fall and fracture risk after 65?

The trial signal and the real-world data point in different directions from the Wegovy label note. In the pooled tirzepatide trials, falls occurred in 3.6% of tirzepatide patients 65 and older versus 3.5% on placebo, and limb fractures in 1.5% versus 3.2% ^[5].

Two observational studies report lower rates. A retrospective cohort using the TriNetX database from January 2018 to July 2025 compared adults 65 and older with type 2 diabetes and BMI of 25 or more on semaglutide or tirzepatide against patients on DPP-4 inhibitors, using 1:1 propensity matching and one-year outcomes ^[8]. Among 27,896 semaglutide pairs, femoral fracture occurred in 0.3% versus 0.5% (HR 0.488, 95% CI 0.367 to 0.649) and falls in 3.6% versus 5.4% (HR 0.663). Among 12,808 tirzepatide pairs, femoral fracture occurred in 0.2% versus 0.4% (HR 0.452, 95% CI 0.280 to 0.729) and falls in 3.6% versus 5.7% (HR 0.664). The fracture reduction was more pronounced in patients with BMI of 30 or higher ^[8].

A separate propensity-matched analysis of 56,142 pairs of women over 50 with osteoporosis found vertebral fracture in about 1.9% of GLP-1 users versus 4.3% of non-users (RR 0.434, 95% CI 0.404 to 0.467), with a similar reduction in kyphoplasty or vertebroplasty (RR 0.453); the authors rated this Level III evidence ^[9].

These are observational associations, not proof that GLP-1s prevent falls or fractures. The TriNetX authors note that clinical trials have largely excluded frail or elderly individuals, and they raise the concern that drug-induced weight loss may reduce skeletal loading and lean mass, potentially increasing frailty and fall risk in older adults ^[8].

What about nutrition and malnutrition during rapid weight loss?

A systematic review and meta-analysis published on 6 September 2026 in Obesity Science and Practice synthesized 19 randomized trials from the SURMOUNT, STEP, SCALE and OASIS programs ^[10]. Daily energy intake fell by 24.00% to 39.20% across drug classes, with model-estimated deficits reaching 1,200 kcal per day. Tirzepatide 15 mg was associated with a mean fat-free mass reduction of 1.60 kg, or 2.80% of body weight ^[10].

Investigator-reported malnutrition was rare, at 0.12% of participants, but objective screening found total lymphocyte counts below 910 per microliter in 2.90% of active-therapy participants versus 1.77% on placebo ^[10]. The authors propose a tiered stepped-care algorithm of baseline albumin and total lymphocyte count screening, with checks at weeks 12, 24 and 52, particularly for adults 65 and older. That monitoring schedule is the study authors’ proposal ^[10].

What about heart failure and dementia signals that matter more with age?

In the pooled tirzepatide trials, which include SUMMIT in heart failure with preserved ejection fraction, heart failure hospitalization occurred in 1.2% of tirzepatide patients 65 and older versus 5.9% on placebo, and the composite of major adverse cardiovascular events in 2.1% versus 3.5% ^[5].

On dementia, a post hoc analysis of the SELECT trial followed 2,970 adults 65 and older with overweight or obesity and cardiovascular disease but no diabetes, randomized to semaglutide 2.4 mg or placebo, measuring a validated 25-protein dementia risk score at baseline and week 104 ^[12]. Predicted five-year dementia risk rose 2.5-fold less with semaglutide (OR 0.74, 95% CI 0.65 to 0.85), and 20-year risk rose 1.67-fold less (OR 0.91, 95% CI 0.88 to 0.94) ^[12]. A proteomic risk score is a biomarker reading, not a dementia diagnosis, and the corresponding author is a Novo Nordisk employee ^[12]. Separately, the evoke and evoke+ trials are investigating oral semaglutide 14 mg in people aged 55 to 85 with early Alzheimer’s disease; those trials are ongoing ^[6].

Does Medicare cover Wegovy or Zepbound, and how does the GLP-1 Bridge work?

Through the Medicare GLP-1 Bridge, a CMS demonstration running from July 1, 2026 to December 31, 2027, eligible Part D beneficiaries pay a $50 copay per one-month supply regardless of income. CMS extended the demonstration through 2027 because the BALANCE Model is not launching in 2027 ^[13][14].

The covered list in the Medicare fact sheet includes the Foundayo tablet, Wegovy injection or tablet, and Zepbound KwikPen only. The single-dose Zepbound pen and Zepbound vials are not covered. Ozempic, Mounjaro and Rybelsus are not on the covered list in the fact sheet ^[14].

Eligibility requires all of the following, per the fact sheet ^[14]:

• Part D drug coverage through a standalone drug plan or a health plan that includes drug coverage, and not only through certain special plan types (private fee-for-service, cost contract or PACE organizations).
• Not already receiving a GLP-1 through the plan. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease should ask their Part D plan, which may already cover a GLP-1 drug.
• Age 18 or older plus one of: BMI 35 or higher; BMI 30 or higher with certain heart failure, hard-to-control high blood pressure or chronic kidney disease stage 3a or above; or BMI 27 or higher with prediabetes or a prior heart attack, stroke or blocked arteries in the legs or arms.

The Bridge operates outside the Part D payment flow, so the Part D deductible does not apply, the $50 does not count toward TrOOP costs or the yearly out-of-pocket limit, there is no low-income subsidy, and these drugs are not eligible for the Medicare Prescription Payment Plan ^[13][14].

The process works like this: the pharmacy checks the Medicare ID number, the doctor submits an approval form to Medicare, and Medicare sends a letter confirming coverage. Refills need no new approval as long as the person stays on the same drug, even if the dose changes. In 2026, CMS is using a single central processor for prior authorization, claims adjudication and pharmacy payment ^[13][14].

Sources

1. Novo Nordisk. Wegovy (semaglutide) prescribing information.
2. Novo Nordisk. Ozempic (semaglutide) prescribing information.
3. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information.
4. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information.
5. Diabetes, Obesity and Metabolism. Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials. 2026.
6. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Safety considerations of semaglutide in the potential treatment of Alzheimer’s disease: A pooled analysis of semaglutide in adults aged ≥ 65 years. 2025.
7. Drugs. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. September 12, 2026.
8. Osteoporosis International. Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes. July 11, 2026.
9. Clinical Spine Surgery. Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis. September 1, 2026.
10. Obesity Science & Practice. A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy. 2026.
11. European Journal of Heart Failure. Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction Across the Age Spectrum: Findings from the STEP-HFpEF Programme.
12. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. Semaglutide attenuates a proteomics-based dementia risk signature in older adults: SELECT trial post hoc analysis. 2026.
13. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
14. Medicare. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month. 2026.
15. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use: highlights of prescribing information. Initial U.S. approval: 2022.